Chairs: J.Y. Blay, FR - P.G. Casali, IT - R.A. Stahel, CH
The “ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is an educational effort, on an annual basis, conceived to strengthen the education of medical professionals willing to devote their career to rare cancers.
Despite being rare as single entities, rare adult solid cancers account for as many as 15% of all new cancer cases, thus being the main group within rare cancers in general. The RARECARE project’s definition and list of 10 “families” of rare adult solid cancers, have been fundamental in shaping the sessions of this course:
• Rare skin cancers & non-cutaneous melanoma
• Rare thoracic tumors
• Rare female genital cancers
• Neuroendocrine tumors
• Endocrine gland tumors
• Digestive rare cancers
• Rare urological and male genital tumors
• Central nervous system neoplasms
• Head & neck cancers
Since ‘networking’ and ‘multidisciplinarity’ are the two keywords to improve quality of care of rare cancers, ESO has decided to develop the programme of this course in collaboration with all the European initiatives in this field and to give its contribution to tackle the rare cancer issue. The “4th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is conceived in the context of, and supported by the Joint Action on Rare Cancers of the European Union (JARC), a project coordinated by the Istituto Nazionale Tumori, Milan, and EURACAN, the European Reference Network on rare adult solid cancers. The Faculty has been largely selected from EURACAN, also with the aim of letting this educational effort closely interact with its networking activities and to help share the best knowledge and updates on these cancers.
The optimal management of rare adult solid cancers poses specific diagnostic and therapeutic challenges, which will be debated and addressed during the course through close interaction between opinion leaders and the participants. The sessions are designed to address the needs of oncologists wanting an update on the advancements in the clinical and research settings.
ESO is also pleased to help with the organization of the 3rd Rare Cancers Europe (RCE) training course for advocacy groups, which will be held in parallel sessions, with the aim to reinforce the relationship and exchange between physicians and patients representatives.
|The course is an ESO-ESMO-RCE joint event|
|Held in collaboration with|
|In the framework of|
M. Angi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
E. Baudin, Institut Gustave Roussy, Villejuif, FR
S. Bielack, Klinikum Stuttgart Olgahospital, Stuttgart, DE
J.Y. Blay, Centre Léon Bérard, Lyon, FR
P. Bruzzi, Istituto Nazionale Ricerca Cancro, Genoa, IT
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Cavalieri, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A.P. Dei Tos, Azienda ULSS9, Treviso, IT
C. De La Fouchardière, Centre Léon Bérard, Lyon, FR
F. De Lorenzo, European Cancer Patient Coalition, Brussels, BE
M. Deraco, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Droz Dit Busset, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
H. Duffau, Hopital Gui de Chauliac, Montpellier, FR
J.G. Eriksen, Aarhus University Hospital, Aarhus, DK
N. Fazio, Istituto Europeo di Oncologia, Milan, IT
A.M. Frezza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
J.A. Gietema, University Medical Center, Groningen, NL
R. Glynne-Jones, Mount Vernon Centre for Cancer Treatment, London, UK
S. Grisanti, A.O. Spedali Civili, Brescia, IT
A. Gronchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A. Idbaih, APHP Hopital de la Salpetriere, Paris, FR
E. Kapiteijn, Leiden University Medical Center, NL
C. Lebbé, Hopital St. Louis, Paris, FR
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
L. Locati, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Newbold, The Royal Marsden NHS Foundation Trust, London, UK
N. Nicolai, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Niger, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Oliver, International Brain Tumour Alliance, Tadworth, UK
F. Peccatori, European School of Oncology, Milan, IT
C. Piazza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Piperno-Neumann, Institut Curie, Paris, FR
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
M. Seckl, Hammersmith Campus, London, UK
R. Soffietti, AOU San Giovanni Battista, Torino, IT
S. Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R.A. Stahel, Cancer Center University Hospital, Zurich, CH
L. Wyrwicz, Marie Curie Memorial Cancer Center, Warsaw, PL
- Medical degree
- Specialization/residency in medical oncology, radiation oncology, surgical oncology or equivalent
Update on the latest clinical development with a background perspective on the state-of-the-art and evidence based practice.
MZ CONGRESSI s.r.l.
ID no. 966
Via Carlo Farini, 81
European School of Oncology
Rare Tumours Programme
c/o Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1
20133 Milano - Italy
Fax +39 0223902531
Fondazione Cariplo Conference Center
Via Romagnosi, 8
The event has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The evaluation of the event has been performed by the Accreditation Council of Oncology in Europe (ACOE) that acknowledged the quality of the scientific programme and its educational value.
The event is designated for a maximum of 16 European CME credits (ECMEC).
Through an agreement between UEMS and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™.
Furthermore, 12 Italian CME credits have been assigned.
The badge is the only official evidence of registration and should be worn at all times during the event.
The organisers bear no responsibility for untoward events in relation to the participation during the Course. Participants are advised to take out their own personal and travel insurance.
The official language will be English. No translation will be provided.
ESO wishes to express its gratitude to Fondazione Cariplo - Iniziative Patrimoniali S.p.A. for their support in hosting the course in its premises.
and to Bayer, Eisai, MSD and PharmaMar for their unrestricted educational grants.
|Early registration:||31 October 2019|
|Save event date:||29 November 2019|
|Early registration by:||insert the date|
|Late registration by:||insert the date|
|Onsite registration from:||insert the date|
Registration grants participation in all sessions, coffee breaks and lunches as indicated in the programme.
Interested oncologists should register online (at the top of this page).
(From 1 November)
|| EUR 250
|| EUR 300
|Club ESO and ESMO Members|| EUR 200
Rates are quoted in Euro and include VAT.
CANCELLATION OF REGISTRATION OR REPLACEMENT
Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee less handling charges of EUR 80 will be refunded after the event, provided that the cancellation is received by ESO before 2 November. Replacements will be possible till 2 November.
PATIENT ADVOCATE REGISTRATION AND TRAVEL GRANT
Please contact RARE CANCERS EUROPE.
For information: firstname.lastname@example.org
|10:30||Registration and coffee entry
|11:00||Welcome from ESO and ESMO
F. Peccatori IT - R.A. Stahel, CH
|INTRODUCTION (plenary session with PAGs)|
|11:20||The problem of rare cancers
P.G. Casali, IT
|11:40||Networking on rare cancers
A.M. Frezza, IT
|12:00||What can we do politically?
F. de Lorenzo, IT - K. Oliver, UK
|12:40||Collaborative clinical registries in rare cancers: the ETOP-NTRK registry
R. Stahel, CH
|UPDATE ON CNS TUMORS
Moderators: R. Soffietti, IT - A. Idbaih, FR
R. Soffietti, IT
|14:20||Rare CNS tumors
A. Idbaih, FR
|14:40||Molecular approaches to CNS tumors
R. Soffietti, IT
|15:00||New developments in surgery of CNS tumors
H. Duffau, FR
|UPDATE ON RARE THORACIC CANCERS
Moderators: M. Garassino, IT - R.A. Stahel, CH
R.A. Stahel, CH
M. Garassino, IT
|UPDATE ON RARE FEMALE GENITAL CANCERS
Moderators: M. Seckl, UK - F. Peccatori, IT
|17:30||Non-epithelial ovarian tumors
I. Ray-Coquard, FR
M. Seckl, UK
|8:30||The scope of pathologic diagnosis in rare cancers:
which molecular profiling should be provided today?
A.P. Dei Tos, IT
|UPDATE ON RARE SKIN TUMORS & UVEAL MELANOMA Moderators: S. Piperno-Neumann, FR - E. Kapiteijn, NL|
|9:00||Merkel cell carcinoma
C. Lebbé, FR
|9:20||Cutaneous adnexal malignancies
S. Cavalieri, IT
M. Angi, IT
|Update on HEAD & NECK CANCERS
Moderators: J.G. Eriksen, DK - L. Licitra, IT
|11:00||Laryngeal & hypopharyngeal carcinoma
L. Licitra, IT
J.G. Eriksen, DK
|11:40||Nasopharyngeal carcinoma & sinonasal cancers
L. Licitra, IT
|12:00||Salivary gland tumors
L. Locati, IT
|12:20||Oral cavity tumors
C. Piazza, IT
|UPDATE ON SARCOMAS
Moderators: P.G. Casali, IT - A. Gronchi, IT
|14:00||Adult soft tissue sarcomas (STS)
P.G. Casali, IT
J.Y. Blay, FR
|14:40||Preoperative chemo-radiation therapy in STS
A. Gronchi, IT
|15:00||Rare bone sarcomas
S. Stacchiotti, IT
|15:20||Ewing sarcoma and Osteosarcoma
S. Bielack, DE
|16:40||Being histologically agnostic in rare cancers
J.Y. Blay, FR
|UPDATE ON ENDOCRINE GLAND TUMORS
Moderators: C. De La Fouchardière, FR - L. Licitra, IT
S. Grisanti, IT
K. Newbold, UK
|8:30||Quality of evidence in rare cancers
|UPDATE ON DIGESTIVE RARE CANCERS
Moderators: L. Wyrwicz, PL - F. de Braud, IT
M. Niger, IT
R. Glynne-Jones, UK
|9:40||Peritoneal mesothelioma & pseudomyxoma peritonei
M. Deraco, IT
|UPDATE ON RARE UROGENITAL CANCERS
Moderators: J.A. Gietema, NL - N. Nicolai, IT
J.A. Gietema, NL
|UPDATE ON NEUROENDOCRINE TUMORS
Moderators: M. Caplin, UK - F. De Braud, IT
|11:40||Thoracic neuroendocrine tumors
E. Baudin, FR
|12:00||Gastroenteropancreatic neuroendocrine tumors
N. Fazio, IT
|12:20||Surgery in neuroendocrine tumors
M. Droz dit Busset, IT